1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Quest PharmaTech Inc. - Product Pipeline Review - 2015

Quest PharmaTech Inc. - Product Pipeline Review - 2015

  • October 2015
  • -
  • Global Markets Direct
  • -
  • 33 pages

Quest PharmaTech Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Quest PharmaTech Inc. - Product Pipeline Review - 2015’, provides an overview of the Quest PharmaTech Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Quest PharmaTech Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Quest PharmaTech Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Quest PharmaTech Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Quest PharmaTech Inc.’s pipeline products

Reasons to buy

- Evaluate Quest PharmaTech Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Quest PharmaTech Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Quest PharmaTech Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Quest PharmaTech Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Quest PharmaTech Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Quest PharmaTech Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Quest PharmaTech Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Quest PharmaTech Inc. Snapshot 5
Quest PharmaTech Inc. Overview 5
Key Information 5
Key Facts 5
Quest PharmaTech Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Quest PharmaTech Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Quest PharmaTech Inc. - Pipeline Products Glance 12
Quest PharmaTech Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Quest PharmaTech Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Quest PharmaTech Inc. - Drug Profiles 15
oregovomab 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
SL-052 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
AR-20.5 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Monoclonal Antibody To Target MUC1 for Oncology 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Monoclonal Antibody to Antagonize HER2/neu for Breast Cancer 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Monoclonal Antibody to Inhibit PSA for Prostate Cancer 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Quest PharmaTech Inc. - Pipeline Analysis 24
Quest PharmaTech Inc. - Pipeline Products by Target 24
Quest PharmaTech Inc. - Pipeline Products by Route of Administration 25
Quest PharmaTech Inc. - Pipeline Products by Molecule Type 26
Quest PharmaTech Inc. - Pipeline Products by Mechanism of Action 27
Quest PharmaTech Inc. - Recent Pipeline Updates 28
Quest PharmaTech Inc. - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
ACP-2127 30
oregovomab 30
Quest PharmaTech Inc. - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Quest PharmaTech Inc., Key Information 5
Quest PharmaTech Inc., Key Facts 5
Quest PharmaTech Inc. - Pipeline by Indication, 2015 7
Quest PharmaTech Inc. - Pipeline by Stage of Development, 2015 8
Quest PharmaTech Inc. - Monotherapy Products in Pipeline, 2015 9
Quest PharmaTech Inc. - Partnered Products in Pipeline, 2015 10
Quest PharmaTech Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11
Quest PharmaTech Inc. - Phase II, 2015 12
Quest PharmaTech Inc. - Phase I, 2015 13
Quest PharmaTech Inc. - Preclinical, 2015 14
Quest PharmaTech Inc. - Pipeline by Target, 2015 24
Quest PharmaTech Inc. - Pipeline by Route of Administration, 2015 25
Quest PharmaTech Inc. - Pipeline by Molecule Type, 2015 26
Quest PharmaTech Inc. - Pipeline Products by Mechanism of Action, 2015 27
Quest PharmaTech Inc. - Recent Pipeline Updates, 2015 28
Quest PharmaTech Inc. - Discontinued Pipeline Products, 2015 30

List of Figures
Quest PharmaTech Inc. - Pipeline by Top 10 Indication, 2015 7
Quest PharmaTech Inc. - Pipeline by Stage of Development, 2015 8
Quest PharmaTech Inc. - Monotherapy Products in Pipeline, 2015 9
Quest PharmaTech Inc. - Partnered Products in Pipeline, 2015 10
Quest PharmaTech Inc. - Pipeline by Top 10 Target, 2015 24
Quest PharmaTech Inc. - Pipeline by Top 10 Route of Administration, 2015 25
Quest PharmaTech Inc. - Pipeline by Top 10 Molecule Type, 2015 26
Quest PharmaTech Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.